The Analgesic Efficacy of Pericapsular Nerve Group (PENG) Block in Patients Undergoing Primary Total Hip Arthoplasty:

The Analgesic Efficacy of Pericapsular Nerve Group (PENG) Block in Patients Undergoing Primary Total Hip Arthoplasty: a Prospective, Double-blinded, Randomized Controlled Trial

Status

Recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06557044

Acronym

PENG

Enrollment

110

Registered

2024-08-16

Start date

2024-03-07

Completion date

2025-03-31

Last updated

2024-08-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Double-blind, Prospective, Randomized

Keywords

Pericapsular Nerve Group Block, hip endoprostheses

Brief summary

The aim of this study is to investigate the analgesic efficacy of the pericapsular nerve group (PENG) block during the implantation of hip endoprostheses. The study is designed as a prospective randomized double-blind study and the study participants were randomized into 2 arms and either 20 ml ropivacaine 0.5% (verum group) or 20 ml physiological saline solution (placebo group) will be applied.

Interventions

DRUGRopivacaine

PENG block with ropivacaine

OTHERPhysiological saline

Placebo control

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* planned cementless hip TEP operation for primary coxarthrosis via minimally invasive anterolateral approach using the identical implant system (Taperloc stem, Plamafit cup) * Patient capable of giving consent * Informed consent has been obtained * age \> 18 years

Exclusion criteria

* Refusal to participate in the study * Regular use of opioids * Known chronic pain symptoms * Infections in the area of the puncture site * Presence of a contraindication to ropivacaine * Presence of a contraindication to metamizole * Presence of a contraindication to postoperative analgesia with diclofenac * Secondary forms of osteoarthritis with deformities (i.e. high-grade dysplasia, secondary conditions after trauma, secondary conditions after childtrauma, secondary conditions after childhood hip joint diseases * Spinopelvic dysbalance, spinal canal stenosis * Previous operations on the hip/pelvis

Design outcomes

Primary

Measure	Time frame	Description
Rate of postoperative opioid administration	60 minutes after arrival in the recovery room	The primary objective is to investigate the influence of the PENG block on the need for postoperative ntravenously opioid administration within the first hour in the recovery room.

Secondary

Measure	Time frame	Description
Quantity of total opioid consumption	until the evening of the second postoperative day	Assessment of total opioid consumption until second postoperative day in both arms
Intensity of postoperative pain	until the evening of the second postoperative day	Subjective perception of postoperative pain, using the numeric rating scale.
Intensity of postoperative nausea and vomiting	until the evening of the second postoperative day	Assessment of postoperative nausea/vomiting using the PONV Score
Postoperative recovery	until the evening of the second postoperative day	Assessment of postoperative recovery using the QoR15 score

Countries

Germany

Contacts

Primary ContactRainer Meierhenrich, Prof. Dr.

meierhenrich@diak-stuttgart.de00497119912290

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026